Latest Breaking News On - Pamela keck - Page 7 : comparemela.com

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating

Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,

United statesSan diegoPlanegg martinsriedPamela keckDoloresj schendelSociety for immunotherapy of cancerPrime standardChief executive officerEnd to platformSwitch proteinsPrecision pairingCellular oncologyDriving forceProgrammed death ligand

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesPlanegg martinsriedPamela keckDoloresj schendelSociety for immunotherapy of cancerPrime standardChief executive officerEnd to platformSwitch proteinsPrecision pairingCellular oncologyDriving forceProgrammed death ligand

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoPlanegg martinsriedPamela keckDoloresj schendelSociety for immunotherapy of cancerPrime standardChief executive officerEnd to platformSwitch proteinsPrecision pairingCellular oncologyDriving forceProgrammed death ligand

Medigene Reports Financial Results and Corporate Update for Q3 2023

Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for.

United statesPamela keckDoloresj schendelPlanegg martinsriedHongsheng sciencesCompany quarterly statementResearch developmentEuropean patent officeEuropean society for medical oncologyEnd to platformPrime standardEuropean societyMedical oncologyChief executive officerCorporate highlightsExecutive management board

Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined

Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,

San diegoUnited statesNew yorkSan diego convention centerMelanie salvermoserPlanegg martinsriedPamela keckGiulia longinottiJulia bittmannMario catarinellaDolores schendelKathrin davariSociety of immunotherapy cancerPrime standardOptimal affinityChief scientific officer